Scarica l'app Stockscreener
11.89
0.25%
-0.03
Neuphoria Therapeutics Inc Borsa (NEUP) Ultime notizie
technical analysis overview for neuphoria therapeutics inc. stock2025 Market WrapUp & Daily Profit Maximizing Trade Tips - Newser
What data driven models say about Neuphoria Therapeutics Inc.’s futureJuly 2025 Patterns & Stock Market Timing Techniques - Newser
How to integrate Neuphoria Therapeutics Inc. into portfolio analysis toolsJuly 2025 Selloffs & Reliable Trade Execution Plans - Newser
What to do if you’re stuck in Neuphoria Therapeutics Inc.Share Buyback & AI Enhanced Market Trend Forecasts - Newser
How to build a dashboard for Neuphoria Therapeutics Inc. stockBull Run & Entry Point Confirmation Alerts - Newser
Will Neuphoria Therapeutics Inc. benefit from macro trendsWeekly Trend Report & AI Powered Market Entry Ideas - Newser
Statistical indicators supporting Neuphoria Therapeutics Inc.’s strength2025 Valuation Update & High Conviction Buy Zone Alerts - Newser
Why is Neuphoria Therapeutics Inc. stock going upPortfolio Update Summary & Expert Approved Trade Ideas - خودرو بانک
Is Neuphoria Therapeutics Inc. being accumulated by smart moneyQuarterly Profit Report & Accurate Intraday Trading Signals - خودرو بانک
Can Neuphoria Therapeutics Inc. recover in the next quarterQuarterly Profit Report & Weekly Market Pulse Updates - Newser
Is Neuphoria Therapeutics Inc. affected by consumer sentimentJuly 2025 PreEarnings & AI Forecast Swing Trade Picks - خودرو بانک
Neuphoria completes enrollment for phase 3 anxiety drug trial By Investing.com - Investing.com Nigeria
Will Neuphoria Therapeutics Inc. outperform the marketWeekly Gains Summary & Breakout Confirmation Trade Signals - Newser
Can momentum traders help lift Neuphoria Therapeutics Inc.IPO Watch & Safe Capital Preservation Plans - Newser
Analyzing recovery setups for Neuphoria Therapeutics Inc. investorsWeekly Profit Recap & Verified Momentum Watchlists - Newser
Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder - MarketScreener
Is Neuphoria Therapeutics Inc. a stock for growth or value investors2025 Investor Takeaways & Capital Protection Trading Alerts - خودرو بانک
Neuphoria completes enrollment for phase 3 anxiety drug trial - Investing.com
Neuphoria Therapeutics achieves target enrollment in AFFIRM-1 Phase 3 trial for BNC-210. - AInvest
Neuphoria Therapeutics Completes Target Enrollment in Phase - GlobeNewswire
Neuphoria Therapeutics Achieves Target Enrollment in Phase 3 AFFIRM-1 Trial for BNC-210 in Social Anxiety Disorder. - AInvest
Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD) - GlobeNewswire Inc.
Using flow based indicators on Neuphoria Therapeutics Inc.Rate Cut & AI Optimized Trading Strategy Guides - Newser
Chart based exit strategy for Neuphoria Therapeutics Inc.July 2025 Analyst Calls & Weekly Chart Analysis and Trade Guides - Newser
Will Neuphoria Therapeutics Inc. continue its uptrend2025 Performance Recap & Verified Trade Idea Suggestions - Newser
Is Neuphoria Therapeutics Inc. attractive for institutional investorsJuly 2025 Trade Ideas & AI Forecasted Entry/Exit Points - خودرو بانک
Technical analysis overview for Neuphoria Therapeutics Inc. stock2025 Market Overview & Precise Swing Trade Entry Alerts - Newser
Is it too late to sell Neuphoria Therapeutics Inc.July 2025 Patterns & Daily Technical Stock Forecast Reports - Newser
Can you recover from losses in Neuphoria Therapeutics Inc.Forecast Cut & Real-Time Volume Spike Alerts - Newser
What is the long term forecast for Neuphoria Therapeutics Inc. stockJuly 2025 Final Week & High Conviction Investment Ideas - خودرو بانک
Has Neuphoria Therapeutics Inc. formed a bullish divergenceEarnings Overview Report & Real-Time Buy Zone Alerts - Newser
How to forecast Neuphoria Therapeutics Inc. trends using time seriesEarnings Trend Report & Stepwise Trade Execution Plans - Newser
Sentiment analysis tools applied to Neuphoria Therapeutics Inc.July 2025 Retail & Safe Capital Investment Plans - Newser
Using portfolio simulators with Neuphoria Therapeutics Inc. included2025 Market Trends & Technical Confirmation Trade Alerts - Newser
Is Neuphoria Therapeutics Inc.’s ROIC above industry average2025 Historical Comparison & Technical Entry and Exit Alerts - خودرو بانک
Exit strategy if you’re trapped in Neuphoria Therapeutics Inc.Weekly Volume Report & Fast Entry and Exit Trade Plans - Newser
Will Neuphoria Therapeutics Inc. benefit from AI trendsPortfolio Return Report & Real-Time Buy Signal Notifications - خودرو بانک
Is Neuphoria Therapeutics Inc. stock ready for a breakoutJuly 2025 Trade Ideas & Free Risk Controlled Daily Trade Plans - Newser
Published on: 2025-09-02 13:20:15 - خودرو بانک
Why Neuphoria Therapeutics Inc. stock attracts strong analyst attentionJuly 2025 Update & Safe Investment Capital Preservation Plans - 한국정경신문
1.40%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):